Case Study 1: The Pharmaceutical Industry and Medicare Drug Pricing (1965-2026)

The setup

When Congress created Medicare in 1965, the program covered hospital care (Part A) and physician services (Part B). Outpatient prescription drugs were not covered. For nearly four decades, this was the central gap in Medicare benefits — and the central frustration of seniors whose drug bills grew steadily as American pharmacology produced more and more outpatient medications.

By the early 2000s, the political pressure to add prescription-drug coverage to Medicare had become irresistible. Both parties recognized that the next major Medicare expansion would have to include drug coverage. The question was: on what terms?

This case study traces the answer to that question — the Medicare Modernization Act of 2003 — and the two decades of pharmaceutical-industry lobbying that built and defended a structural feature of that law: the non-interference clause that prohibited Medicare from negotiating drug prices. The case is a near-perfect illustration of how organized interest-group activity shapes major federal legislation, how the revolving door operates at the policy level, and how — eventually — durable interest-group dominance can be overcome under specific political conditions.

The Medicare Modernization Act of 2003

The Medicare Modernization Act (MMA) added what came to be called Medicare Part D: a prescription-drug benefit, delivered through private insurance plans, with subsidies for low-income beneficiaries. The MMA passed the House by a 220-215 vote on November 22, 2003 — a vote held open for nearly three hours, much longer than House rules contemplated, while the Republican leadership pressured holdouts. It passed the Senate 54-44.

The bill was supported by President George W. Bush as a major domestic-policy achievement of his first term, by the Republican congressional leadership, and — critically — by the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry's principal trade association.

PhRMA's support was not free. It was conditional on a specific provision: Section 1860D-11(i) of the new statute, which read in relevant part:

"In order to promote competition under this part... the Secretary [of Health and Human Services] may not interfere with the negotiations between drug manufacturers and pharmacies and PDP [prescription drug plan] sponsors, and may not require a particular formulary or institute a price structure for the reimbursement of covered Part D drugs."

This is the non-interference clause, sometimes called the "non-negotiation provision." It prohibited the largest single drug purchaser in the United States — Medicare, covering tens of millions of beneficiaries — from using its market power to negotiate drug prices. Private insurers running individual Part D plans could negotiate prices for their plan; Medicare itself could not negotiate aggregate prices on behalf of the entire program.

The Veterans Health Administration, which is permitted to negotiate prices, was at the time paying roughly 40% less for the same drugs than Medicare Part D plans were paying after the MMA took effect. The price difference was widely understood. The non-interference clause locked it in.

The lobbying campaign

PhRMA's annual lobbying expenditures during the run-up to the MMA were substantial — roughly $35-50 million per year in the 2002-2004 period, augmented by individual-company lobbying expenditures in the same range. The industry's combined federal lobbying expenditures during this period totaled roughly $150-200 million per year across PhRMA, the Biotechnology Industry Organization, and individual pharmaceutical and biotech companies.

The lobbying campaign included direct contact with members and staff (well-documented in House and Senate office logs of the period), issue advertising aimed at the public ($60+ million in TV spending in the months leading up to the vote), academic-affiliated research arguing that price negotiation would reduce pharmaceutical innovation, coalition-building with patient-advocacy groups (some of which received substantial pharmaceutical-industry funding), and intensive engagement with the Bush administration's policy team.

The revolving door operated visibly. Representative Billy Tauzin (R-LA), the chair of the House Energy and Commerce Committee that wrote much of the MMA, retired from Congress in 2005 and almost immediately took the position of president and CEO of PhRMA at a reported salary of approximately $2 million per year — a salary that drew bipartisan criticism at the time, including pointed remarks from then-Representative John Conyers and from conservative columnist George Will. Tauzin held the PhRMA position until 2010. The cooling-off period in effect at the time was the pre-HLOGA 1-year rule for House members, which Tauzin satisfied. The optics, however, were not good.

Tauzin was not the only example. A 2005 Knight Ridder investigation found that at least 17 senior congressional staff and members involved in drafting the MMA went on to lobbying or industry positions within a few years, including Tom Scully (administrator of the Centers for Medicare and Medicaid Services during the MMA drafting, who joined a private equity firm with substantial pharmaceutical investments) and several senior Senate Finance Committee staffers.

The defense and the entrenchment

For the next two decades, every effort to repeal or modify the non-interference clause failed. The 2009-2010 Affordable Care Act fight saw a particularly notable round of negotiation. The Obama administration, in a controversial move that surfaced through reporting after the law's passage, made an explicit deal with PhRMA: in exchange for the industry's neutrality (and modest financial contributions to the law's coverage expansions), the ACA would not include direct Medicare drug-price negotiation. The deal — sometimes called the "PhRMA deal" — was central to the law's passage.

Progressive critics of the deal (Howard Dean, Jane Hamsher, others) argued at the time that the administration had given away the industry's most vulnerable point in exchange for short-term political quiet. Defenders of the deal argued that without industry neutrality, the ACA would not have passed at all, and that securing 20 million people's healthcare coverage was worth deferring the drug-pricing fight. Both sides had a point. The political reality was that PhRMA had built a structural position — the non-interference clause and the political coalition defending it — that any major healthcare reform had to navigate around.

In the 2017-2020 period, both parties' presidential candidates promised drug-price reform. President Trump in 2018 announced a "blueprint" for drug-pricing reform that included international reference pricing and other measures; most of the proposals were either blocked judicially, withdrawn, or implemented in attenuated form. Senator Sanders made drug-pricing reform a major campaign theme. The political will was clearly building. The legislative path remained blocked.

The IRA breakthrough

In 2022, the political conditions finally aligned. The Inflation Reduction Act (IRA), passed by the Democratic-controlled 117th Congress through the budget reconciliation process and signed by President Biden, did three things on drug pricing:

1. Allowed Medicare to negotiate prices for a small but growing list of prescription drugs (10 drugs starting in 2026, expanding to 20 in 2027 and beyond), focused on high-spend drugs that have been on the market without generic competition for at least 7 years (small molecules) or 11 years (biologics).
2. Capped insulin co-pays for Medicare beneficiaries at $35 per month.
3. Required pharmaceutical manufacturers to pay rebates to Medicare if they raise drug prices faster than inflation.

The drug-price negotiation provision was not the comprehensive Medicare-negotiation regime that progressives had sought. It was substantially narrower — a defined list of drugs, after defined exclusivity periods, with a defined "maximum fair price" methodology. The non-interference clause was not repealed; it was carved-out for the negotiated drugs.

But it was real. For the first time since 2003, Medicare could negotiate the price of some drugs. The first ten drugs subject to negotiation were announced in August 2023; the negotiated prices took effect January 2026. The CBO estimated that the IRA's drug-pricing provisions would save Medicare approximately $100 billion over the decade.

The continuing litigation

The pharmaceutical industry did not accept the IRA quietly. As of early 2026, multiple lawsuits are pending challenging the Medicare drug-negotiation provisions. The plaintiffs include Merck, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, and the U.S. Chamber of Commerce. The legal theories advanced include:

• First Amendment compelled-speech claims (the law's "agreements" between manufacturers and Medicare are claimed to compel manufacturers to falsely describe negotiated prices as voluntary).
• Fifth Amendment takings claims (the maximum-fair-price methodology is claimed to confiscate property without just compensation).
• Eighth Amendment excessive-fines claims (the excise-tax penalty for non-compliance is claimed to be punitively excessive).
• Due process challenges to the procedures by which the negotiation operates.

Lower-court rulings have largely favored the government. The Court of Appeals for the Federal Circuit and several circuit courts have rejected most of the constitutional challenges. As of early 2026, the Supreme Court has not yet granted certiorari on any of these cases, but observers expect it will eventually take one or more.

What the case shows

The pharmaceutical drug-pricing story illustrates several structural features of the modern lobbying ecosystem:

Concentrated interests can defend structural advantages for decades. PhRMA and individual pharmaceutical companies maintained the non-interference clause for nineteen years, against repeated attempts to repeal it, across both Republican and Democratic congressional majorities. The defense was constitutionally legitimate, well-funded, expertly executed, and sustained by an institutional infrastructure that included think-tank research, patient-advocacy alliances, and continuous direct lobbying. The system worked exactly as the First Amendment permits.

The revolving door supplies the talent. Tauzin's transition from Energy and Commerce chair to PhRMA CEO was unusual in its visibility, not in its pattern. The senior staff and former officials who staffed PhRMA's lobbying operation throughout the 2003-2022 period brought genuine expertise in Medicare policy, congressional process, and regulatory law. The expertise was real. The structural alignment of interests was also real.

Eventually, persistent political pressure can overcome durable structural advantages. Two decades of advocacy, public-opinion movement, and legislative effort eventually produced a (partial) reform. The IRA negotiation provisions are narrower than reformers wanted, but they are real. The lesson is not that lobbying is omnipotent — clearly it is not — but that the timelines on which entrenched lobbying coalitions are overcome are long.

Litigation is the next phase. Even after legislative reform, the affected industries continue the fight in the courts. The IRA's drug-pricing provisions will be tested by a Supreme Court that includes justices skeptical of administrative-state authority and constitutionally protective of property and speech rights. The eventual outcome is uncertain.

Both sides have legitimate constitutional positions. PhRMA and its member companies are exercising First-Amendment-protected speech and petition activity, defending what they regard as legitimate property interests in their products and pricing structures. Medicare-negotiation advocates are exercising the same First-Amendment-protected speech and petition activity, advocating what they regard as a legitimate exercise of the federal government's spending power on behalf of taxpayers and beneficiaries. The disagreement is real, durable, and not resolvable by appeal to the Constitution alone. It will be resolved through the political and judicial processes — exactly as the system is designed to do, even if the resolution takes decades and even if the outcome reflects asymmetric organized power.

The pharmaceutical industry will continue to lobby. Medicare-negotiation advocates will continue to advocate. The lobbying ecosystem the chapter describes is the system within which both will operate. The story of Medicare drug pricing is, in microcosm, the story of how that ecosystem produces — eventually, and unevenly — policy outcomes that reflect both the asymmetry of organized power and the persistent ability of democratic majorities to push back.